Journal
VACCINE
Volume 22, Issue 3-4, Pages 370-377Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2003.08.004
Keywords
hepatitis E virus (HEV); virus-like particles (VLPs); oral immunization; vaccine
Categories
Ask authors/readers for more resources
Hepatitis E virus (HEV) is an important causative agent of enterically-transmitted hepatitis. Successful vaccine development is crucial in controlling global HEV infection. HEV capsid protein, with I I I amino acids truncated at the N-terminus, was efficiently expressed in the baculovirus expression system [J. Virol. 71 (1997) 7207-13]. Expressed protein spontaneously assembled into virus-like particles (VLPs) and was released into culture medium. When cynomolgus monkeys were orally inoculated with 10 mg of purified rHEV VLPs, serum IgM, IgG, and IgA responses were observed. All these antibody responses were obtained without adjuvants. When the monkeys were challenged with native HEV by intravenous injection, they were protected against infection or developing hepatitis. These results suggested that recombinant HEV (rHEV) VLPs can be a candidate for the oral hepatitis E vaccine. (C) 2003 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available